Sana Bio Files 8-K on Material Agreement; Details Undisclosed

TL;DR

**SANA just filed an 8-K about a material agreement, but they're not saying what it is yet.**

AI Summary

Sana Biotechnology, Inc. filed an 8-K on February 8, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on February 7, 2024. While the filing indicates a significant agreement, it does not disclose the specific details of the agreement or the other events. This lack of detail means investors are currently in the dark about the nature and potential impact of this material agreement, which could affect the company's future prospects and stock price.

Why It Matters

This filing signals a potentially significant business development for Sana Biotechnology, Inc., but without specific details, investors cannot assess its financial or strategic implications.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement without disclosing its terms, creating uncertainty and potential for future stock volatility once details emerge.

Analyst Insight

A smart investor would monitor Sana Biotechnology, Inc. closely for subsequent filings or press releases that disclose the specifics of the 'Material Definitive Agreement' to understand its potential impact before making investment decisions.

Key Players & Entities

• Sana Biotechnology, Inc. (company) — the registrant filing the 8-K
• February 7, 2024 (date) — date of the earliest event reported
• February 8, 2024 (date) — date the 8-K was filed
• 001-39941 (other) — Commission File Number for Sana Biotechnology, Inc.

Forward-Looking Statements

• Sana Biotechnology, Inc. will release further details about the 'Material Definitive Agreement' within the next 30 days. (Sana Biotechnology, Inc.) — medium confidence, target: 2024-03-08

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SANA The Nasdaq
• $5.50 — per share, at a price to the public of $5.50 per share (the "Underwritten Shares"),
• $5.4999 — ommon stock at a price to the public of $5.4999 per underlying share. Under the terms o
• $5.17 — n Shares from the Company at a price of $5.17 per share and the Pre-Funded Warrants a
• $5.1699 — d the Pre-Funded Warrants at a price of $5.1699 per underlying share. In addition, the
• $156.6 m — fering are expected to be approximately $156.6 million, after deducting underwriting dis

Filing Documents

• d745670d8k.htm (8-K) — 37KB
• d745670dex11.htm (EX-1.1) — 194KB
• d745670dex41.htm (EX-4.1) — 74KB
• d745670dex51.htm (EX-5.1) — 11KB
• d745670dex991.htm (EX-99.1) — 7KB
• g745670g0208032652986.jpg (GRAPHIC) — 1KB
• g745670g0208032653139.jpg (GRAPHIC) — 3KB
• 0001193125-24-028506.txt ( ) — 538KB
• sana-20240207.xsd (EX-101.SCH) — 3KB
• sana-20240207_lab.xml (EX-101.LAB) — 18KB
• sana-20240207_pre.xml (EX-101.PRE) — 11KB
• d745670d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits See the Exhibit Index below, which is incorporated by reference herein. EXHIBIT INDEX Exhibit No. Description 1.1 Underwriting Agreement, dated as of February 7, 2024, among Sana Biotechnology, Inc. and the Representatives. 4.1 Form of Pre-Funded Warrant . 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, P.C. 23.1 Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1). 99.1 Press Release dated February 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sana Biotechnology, Inc. Date: February 8, 2024 By: /s/ Bernard J. Cassidy Bernard J. Cassidy Executive Vice President and General Counsel